- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Durvalumab, Oleclumab, Monalizumab, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,051 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 33
- States / cities
- San Diego, California • New Haven, Connecticut • Stuart, Florida + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,961
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Colorectal Cancer
- Interventions
- bevacizumab, cetuximab, FOLFIRI regimen, FOLFOX regimen, capecitabine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, mitomycin C, oxaliplatin, therapeutic conventional surgery
- Biological · Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Winston-Salem, North Carolina
- Conditions
- Cutaneous Surgery
- Interventions
- Electrodesiccation and Curettage vs Excision
- Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Choroidal Neovascularization
- Interventions
- Faricimab, Ranibizumab, Sham Procedure
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 46 more
- Conditions
- NSCLC, Non-small Cell Lung Cancer, Lung Cancer
- Interventions
- MEDI4736, tremelimumab
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 459 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 22 more
- Conditions
- Major Depression, Dysthymia
- Interventions
- ADAPt-C intervention
- Behavioral
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 472 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Multiple Myeloma
- Interventions
- Cevostamab, Tocilizumab, Pomalidomide, Daratumumab, Dexamethasone
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 6
- States / cities
- Duarte, California • Irvine, California • Denver, Colorado + 3 more
- Conditions
- Necrotizing Soft Tissue Infection, Sepsis
- Interventions
- HAT, Placebo
- Drug
- Lead sponsor
- Ascension Health
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Wichita, Kansas
- Conditions
- Cancer
- Interventions
- Pre-Test Intervention, Standard of Care, Post-Test Intervention
- Other
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Informed Consent, Comprehension, Communication, Disclosure
- Interventions
- Original ICF, AI Simplified ICF, Podcast - Original ICF, Podcast - Simplified ICF
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- Navlimetostat, Gemcitabine, Nab-paclitaxel, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 48
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Springdale, Arkansas + 38 more
- Conditions
- Carcinoma, Non-small Cell Lung Cancer
- Interventions
- nivolumab, ipilimumab, cabozantinib, docetaxel, ramucirumab, lucitanib
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Autism Spectrum Disorder
- Interventions
- Opt-In Early Latinx intervention, Opt-In Early Rural Intervention
- Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 15 Months and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Hartford, Connecticut • Portland, Oregon
- Conditions
- Bacillus Anthracis (Anthrax)
- Interventions
- BioThrax®
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 328 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Cincinnati, Ohio • Houston, Texas + 1 more
- Conditions
- Chronic Hepatitis C
- Interventions
- Debio 025, Peg-IFNα2a, Ribavirin
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 7
- States / cities
- La Jolla, California • Gainesville, Florida • Miami, Florida + 4 more
- Conditions
- Smoking, Smoking Cessation, HIV
- Interventions
- Nicoderm C-Q Transdermal Product, Adherence to Antiretroviral Therapy Counseling, Behavioral Smoking Cessation Counseling, "Crave-to-Quit" app, vDOT "emocha" app
- Drug · Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Trauma, Insomnia, Nightmares
- Interventions
- Cognitive Processing Therapy-Cognitive Only (CPT), Cognitive Behavioral Therapy of Insomnia and Nightmares (CBTin), Continuation Cognitive Processing Therapy-Cognitive Only (CPT)
- Behavioral
- Lead sponsor
- University of North Texas, Denton, TX
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Fort Hood, Texas
- Conditions
- Diabetic Macular Edema
- Interventions
- Low dose BI 3812465, Medium dose BI 3812465, High dose BI 3812465
- Biological
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Arcadia, California + 25 more
- Conditions
- HER2-positive Breast Cancer
- Interventions
- Omission of Radiation
- Radiation
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Follicular Lymphoma, Diffuse Large B-Cell Lymphoma
- Interventions
- Obinutuzumab, Pinatuzumab Vedotin, Polatuzumab Vedotin, Rituximab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Stanford, California • Denver, Colorado + 21 more
- Conditions
- COVID-19
- Interventions
- Vaccine Messaging, Vaccine Acceptance Question
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 919 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 7
- States / cities
- San Francisco, California • Durham, North Carolina • Philadelphia, Pennsylvania + 1 more
- Conditions
- Alcohol Exposed Pregnancy
- Interventions
- Native WYSE CHOICES
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 16 Years to 20 Years · Female only
- Enrollment
- 439 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Difficult Airway
- Interventions
- C-MAC, Glidescope
- Device
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1,100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy, vudalimab + docetaxel, vudalimab + cabazitaxel or docetaxel
- Combination Product · Biological
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 26
- States / cities
- Anchorage, Alaska • Glendale, Arizona • Phoenix, Arizona + 23 more